Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May:47:100761.
doi: 10.1016/j.blre.2020.100761. Epub 2020 Oct 8.

Coagulation and anticoagulation in COVID-19

Tarik Hadid  1 , Zyad Kafri  2 , Ayad Al-Katib  3
Affiliations
Review

Coagulation and anticoagulation in COVID-19

Tarik Hadid et al. Blood Rev. 2021 May.

Abstract

COVID-19 has become a pandemic in the United States and worldwide. COVID-19-induced coagulopathy (CIC) is commonly encountered at presentation manifested by considerable elevation of D-dimer and fibrin split products but with modest or no change in activated partial thromboplastin time and prothrombin time. CIC is a complex process that is distinctly different from conventional sepsis-induced coagulopathy. The cytokine storm induced by COVID-19 infection appears to be more severe in COVID-19, resulting in development of extensive micro- and macrovascular thrombosis and organ failure. Unlike conventional sepsis, anticoagulation plays a key role in the treatment of COVID-19, however without practice guidelines tailored to these patients. We propose a scoring system for COVID-19-coagulopathy (CIC Scoring) and stratification of patients for the purpose of anticoagulation therapy based on risk categories. The proposed scoring system and therapeutic guidelines are likely to undergo revisions in the future as new data become available in this evolving field.

Keywords: Anticoagulation; COVID-19; COVID-19 induced coagulopathy; Coagulation; Coagulopathy; Thrombosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
A proposed algorithm to triage COVID-19 for the purpose of anticoagulation.
See this image and copyright information in PMC

References

    1. Cui J., Li F., Shi Z.-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17:181–192. - PMC - PubMed
    1. Yin Y., Wunderink R.G. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23:130–137. - PMC - PubMed
    1. Song Z., Xu Y., Bao L., Zhang L., Yu P., Qu Y. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019;11 - PMC - PubMed
    1. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513. - PMC - PubMed
    1. Xu X., Chen P., Wang J., Feng J., Zhou H., Li X. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63:457–460. - PMC - PubMed

MeSH terms

Substances